© Alibion AG 2018

Pipeline 

ALB001

We are currently developing ALB001 as the first personalized medicine against Rheumatoid arthritis. Our molecule was developed jointly by Dr. Holoshitz and Dr. White at the University of Michigan. ALB001 has achieved preclinical proof of concept in animal models and is ready to begin IND-enabling safety studies. We expect to potentially initiate first-in-human trials by 2021.